News

Subject to stockholder approval, the combined company will advance a pipeline of novel inhalation therapies for the treatment of diseases with significant unmet medical needs, featuring three product

Amgen which filed the lawsuit against the joint developers of Praulent got the injunction in its favor in the US District Court in Delaware. The California based company

Lucentis is the first FDA-approved anti-vascular endothelial growth factor (VEGF) therapy to treat mCNV in the U.S. This is the fifth FDA-approved indication for Lucentis since the medicine

PNH is a debilitating, ultra-rare, life-threatening blood disorder in which uncontrolled activation of complement, a component of the immune system, results in hemolysis (destruction of a patient’s red

The Swiss drugmaker signed a collaboration and option agreement, which is subject to customary closing conditions and regulatory approvals. Ionis developed two investigational antisense therapies, dubbed AKCEA-APO(a)-LRx and

Humira is currently approved in the US, the European Union and other markets for arthritis related problems and other indications. The investigational compound PF-06410293, a monoclonal antibody (mAb), met

SGN-CD352A is an investigational CD352-targeted antibody-drug conjugate (ADC) utilizing Seattle Genetics’ proprietary ADC technology, an engineered cysteine antibody (EC-mAb) stably linked to a highly potent cytotoxic agent called

Under the terms of the development agreement, PvP will conduct all research and development through phase 1 proof-of-principle studies per a pre-defined development plan. Takeda will fund $35

Meeting minutes received from the FDA’s Division of Anti-Infective Products confirmed key elements of the company’s overall plan for benznidazole, including: The company’s proposed 505(b)(2) approach to demonstrate